- Home
- LEGN vs BPMC Comparison
LEGN vs BPMC Comparison
Compare LEGN & BPMC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LEGN
- BPMC
- Stock Information
- Founded
- LEGN 2014
- BPMC 2008
- Country
- LEGN United States
- BPMC United States
- Employees
- LEGN N/A
- BPMC N/A
- Industry
- LEGN Biotechnology: Pharmaceutical Preparations
- BPMC Biotechnology: Pharmaceutical Preparations
- Sector
- LEGN Health Care
- BPMC Health Care
- Exchange
- LEGN Nasdaq
- BPMC Nasdaq
- Market Cap
- LEGN 7.0B
- BPMC 5.8B
- IPO Year
- LEGN 2020
- BPMC 2015
- Fundamental
- Price
- LEGN $32.80
- BPMC $84.69
- Analyst Decision
- LEGN Strong Buy
- BPMC Buy
- Analyst Count
- LEGN 12
- BPMC 22
- Target Price
- LEGN $79.00
- BPMC $124.48
- AVG Volume (30 Days)
- LEGN 1.6M
- BPMC 1.2M
- Earning Date
- LEGN 05-12-2025
- BPMC 05-01-2025
- Dividend Yield
- LEGN N/A
- BPMC N/A
- EPS Growth
- LEGN N/A
- BPMC N/A
- EPS
- LEGN N/A
- BPMC N/A
- Revenue
- LEGN $627,241,000.00
- BPMC $508,824,000.00
- Revenue This Year
- LEGN $66.92
- BPMC $45.70
- Revenue Next Year
- LEGN $51.77
- BPMC $31.83
- P/E Ratio
- LEGN N/A
- BPMC N/A
- Revenue Growth
- LEGN 119.97
- BPMC 104.04
- 52 Week Low
- LEGN $29.27
- BPMC $73.04
- 52 Week High
- LEGN $60.87
- BPMC $121.90
- Technical
- Relative Strength Index (RSI)
- LEGN 45.92
- BPMC 47.15
- Support Level
- LEGN $29.27
- BPMC $78.66
- Resistance Level
- LEGN $35.11
- BPMC $83.50
- Average True Range (ATR)
- LEGN 1.89
- BPMC 5.00
- MACD
- LEGN 0.16
- BPMC 0.20
- Stochastic Oscillator
- LEGN 60.48
- BPMC 67.15
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.
About BPMC Blueprint Medicines Corporation
Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates includes AYVAKIT for the treatment of systemic mastocytosis, BLU-808 a potential treatment for mast cell disorders, including chronic urticaria, sleep disruption and other related diseases. It also has other drugs in its pipeline such as BLU-956, BLU-222 for treatment of breast cancer.